1. Home
  2. TMHC vs IMVT Comparison

TMHC vs IMVT Comparison

Compare TMHC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taylor Morrison Home Corporation

TMHC

Taylor Morrison Home Corporation

HOLD

Current Price

$71.58

Market Cap

5.5B

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$35.34

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TMHC
IMVT
Founded
1936
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.8B
IPO Year
2012
2019

Fundamental Metrics

Financial Performance
Metric
TMHC
IMVT
Price
$71.58
$35.34
Analyst Decision
Buy
Buy
Analyst Count
7
8
Target Price
$71.71
$33.00
AVG Volume (30 Days)
4.8M
1.6M
Earning Date
04-22-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.01
N/A
Revenue
$4,762,059,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$8.96
N/A
P/E Ratio
$70.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$54.15
$14.32
52 Week High
$72.27
$36.29

Technical Indicators

Market Signals
Indicator
TMHC
IMVT
Relative Strength Index (RSI) 74.12 65.44
Support Level $57.45 $25.13
Resistance Level $72.04 $36.29
Average True Range (ATR) 0.28 1.47
MACD 0.09 0.16
Stochastic Oscillator 18.07 91.93

Price Performance

Historical Comparison
TMHC
IMVT

About TMHC Taylor Morrison Home Corporation

Taylor Morrison Home Corp is an American residential construction company engaged in residential homebuilding and the development of lifestyle communities. It designs, builds, and sells single and multi-family detached and attached homes in traditionally high growth markets for entry level, move-up, and resort lifestyle buyers. The company has four reportable segments: East, Central, West, and Financial Services. The majority of the company's revenue is derived from its West Segment.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: